TLR4 and breast carcinoma: TLR4 antagonist ATL I inhibits the TLR4/NF-κB signaling pathway in breast cancer cells and reduces NF-κB-regulated cytokines, cell proliferation, migration, invasion, and promotes apoptosis, leading to an anti-breast cancer effect [55].